Welcome to our dedicated page for MOLECULAR PARTNERS SEC filings (Ticker: MOLN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SEC filings page for Molecular Partners AG (MOLN) brings together the companys U.S. regulatory disclosures, offering a detailed view of its financial position, risk factors and development activities. As a foreign private issuer listed on the Nasdaq Global Select Market, Molecular Partners files annual reports on Form 20-F and interim reports on Form 6-K, which include financial statements, business updates and information on key collaborations.
In its condensed consolidated interim financial statements furnished on Form 6-K, Molecular Partners describes itself as a clinical-stage biopharmaceutical company pioneering DARPin candidates to treat serious diseases, with a current focus on oncology and virology. These filings provide IFRS-based financial data such as cash and cash equivalents, research and development expenses, selling, general and administrative expenses, restructuring charges and net results attributable to shareholders, along with statements of financial position, profit or loss and cash flows.
The company also uses Form 6-K to furnish press releases that summarize clinical pipeline progress and corporate developments. These exhibits cover topics such as the status of the MP0712 Radio-DARPin program targeting DLL3, the MP0533 multispecific T cell engager trial in relapsed/refractory AML and MDS/AML, the MP0317 tumor-localized CD40 agonist, and Switch-DARPin preclinical data. Filings reference co-development and license agreements, including those with Orano Med and Novartis, and discuss how these arrangements are reflected in revenue from research and development collaborations.
On Stock Titan, investors can use AI-powered tools to quickly interpret Molecular Partners lengthy SEC documents. Real-time ingestion of new 6-K and 20-F filings from EDGAR enables timely access to updated financials and corporate disclosures, while AI-generated highlights help users focus on key items such as changes in operating expenses, cash runway commentary, collaboration terms and pipeline-related risk discussions.
Molecular Partners AG reports clinical pipeline progress and a solid cash position. The company had cash and cash equivalents of CHF 93.1 million as of December 31, 2025 (unaudited), which it expects will fund operations into 2028. Several programs are advancing: the Phase 1/2a trial of lead Radio-DARPin MP0712 in small cell lung cancer has started in the US, with first patient dosing expected in Q1 2026 and initial clinical data anticipated in 2026, supported by encouraging compassionate-use imaging that showed targeted tumor delivery.
The Radio-DARPin pipeline also includes MP0726 targeting mesothelin, with plans to move multiple radiotherapy programs toward first-in-human imaging and guidance from a newly formed scientific advisory board. An investigator-initiated Phase 2 trial of MP0317 in advanced cholangiocarcinoma is open in France, aiming to enroll 75 patients in combination with durvalumab plus chemotherapy. MP0533, a tetra-specific T cell engager for AML, is in an ongoing Phase 1/2a study, with densified dosing showing tolerability and preliminary antitumor activity and a development update planned for H1 2026. The company also plans to nominate a first Switch-DARPin candidate for development in H1 2026.
Molecular Partners AG furnished a press release and unaudited condensed interim financials for the three and nine months ended September 30, 2025. The company reported a net loss of CHF 49,002 thousand for the nine-month period and CHF 11,836 thousand for the quarter. Revenues were nil after prior-period collaboration income ended, while operating expenses totaled CHF 45,502 thousand year-to-date, including a CHF 2,733 thousand restructuring charge tied to a June 2025 efficiency initiative.
Research and development expense was CHF 30,954 thousand and selling, general and administrative expense was CHF 11,815 thousand for the nine months. Basic and diluted net result per share was CHF (1.32) year-to-date and CHF (0.33) in the quarter. Cash and cash equivalents were CHF 82,359 thousand with short-term time deposits of CHF 22,162 thousand as of September 30, 2025. Net cash used in operating activities was CHF 40,106 thousand for the nine months, partly offset by movements in time deposits, leading to a period-end cash balance increase from January 1.
Total shareholders’ equity was CHF 95,529 thousand at quarter-end. Collaboration with Novartis ended in 2024, and the company recorded no revenue from that agreement in 2025.
Molecular Partners (MOLN) reported H1 2025 results showing continued investment in its DARPin drug platform and a solid cash runway. The company has CHF 114.5 million in cash and short-term deposits as of June 30, 2025 and expects to be funded into 2028 excluding potential partner receipts. In H1 2025 it used CHF 30.2 million in operating cash, recorded an operating loss of CHF 33.5 million and a net loss of CHF 37.2 million, and recognized CHF 2.6 million of restructuring expenses. Development highlights include a co-development with Orano Med on 212Pb Radio-DARPin candidates MP0712 (DLL3) and MP0726 (MSLN), positive preclinical MP0712 data presented at AACR 2025, ongoing FDA dialogue with an IND filing for MP0712 expected in Q3 2025 and first-in-human dosing planned in 2025 pending clearance, with initial clinical data expected in H1 2026. H1 2025 financial statements are available on the company's website.
Molecular Partners AG has filed an S-8 registration statement to register securities related to three employee benefit plans: Performance Share Plan 2025 for Employees, Performance Share Plan 2025 for Management, and Restricted Share Plan 2025.
Key details of the filing:
- Filed on June 25, 2025 for Swiss-based biotech company trading under symbol MOLN
- Registration covers three distinct employee benefit plans introduced in 2025
- Company maintains principal executive offices in Zurich-Schlieren, Switzerland with U.S. presence in Cambridge, Massachusetts
- Filing incorporates by reference the company's annual report on Form 20-F for FY2024 and recent Form 6-K reports
The registration is signed by CEO Patrick Amstutz and includes signatures from the full board of directors, including Chairman William Burns. The company has appointed legal representation from Cooley LLP (US) and Homburger AG (Switzerland) for this filing. This registration enables Molecular Partners to offer equity-based compensation to both employees and management under these newly established plans.
FAQ
What is the current stock price of MOLECULAR PARTNERS (MOLN)?
What is the market cap of MOLECULAR PARTNERS (MOLN)?
